Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. M. (Michiel) Rienstra

Research interests

Michiel Rienstra graduated in medicine (cum laude) at the University of Antwerp, Belgium in 2003, graduated master of health administration in 2021 at TIAS School for Business and Society, The Netherlands. Obtained a PhD at the University of Groningen, The Netherlands in 2007 on Atrial Fibrillation, Underlying Disease and Prognosis. He completed his cardiology training at the University Medical Center Groningen in 2012, followed by training as device cardiologist, where continued working as clinical cardiologist and researcher. He is a Professor of Clinical Cardiology at the University of Groningen, past-Clinical Director of the Department of Cardiology, and cardiologist at the University Medical Center Groningen, specialized in AF, devices and advanced HF. He combines treatment of patients with arrhythmias and HF with clinic-oriented AF and HF research. He is founder of the regional network HeartNet Northern-Netherlands (since 2018) aiming to integrate care and value-based heath care for inhabitants at risk and patients with cardiovascular diseases in the 2 Northern provinces of the Netherlands. Stakeholders of the network are patient organisations, cardiologists, general practitioner cooperation’s, and health insurance companies. His research consists of conducting investigator-initiated clinical studies to improve AF or HF treatment (steeringcie/principal investigator of RACE I to V, CONVERT, VIP-HF, MARC, DECISION, RACE 7-ACWAS, DUTCH-AF), studying epidemiology of AF and its risk factors (including HF) in PREVEND, Lifelines and Framingham Heart Study, uncovering the genetics of AF in part with the AFGen international consortium (contributor since NWO-Rubicon fellowship in Boston), and applying novel bioinformatics tools to improve AF risk prediction using biobanks of AF patients (AF-Risk, Biomarker-AF, Young-AF). He was awarded with a NWO-VENI grant for a project on genetics of AF, followed by European Society of Cardiology academic grant for a project on a big data approach in AF. He is involved in several national consortia (Cardiovascular Research Netherlands - CVON): CVON-RACE V (hypercoagulability and AF progression), CVON-RED-CVD (early detection of cardiovascular disease in general practices), and CVON-AI (Catalyzing the application of Artificial Intelligence for Cardiovascular Research Netherlands), and co-PI of the DECISION (Digoxin Evaluation in Chronic Heart Failure: Investigational Study in Outpatients in the Netherlands), and steering committee member of numerous investigator-initiated studies (RACE 8, RACE 9, MARC 2 and CABA-HFPEF). He is PI of the national AF-network EmbRACE in the Netherlands. He is fellow of the European Society of Cardiology and the American Heart Association. He is research coordinator for the European Society of Cardiology 2024 guidelines on management of AF.


Research consists of conducting clinical studies and trials to improve AF treatment, also in the setting of HF; studying the epidemiology of AF and its risk factors (with emphasis on HF) in PREVEND, Lifelines; uncvering the genetics of AF within the international AFGen/TOPMED consortia; and applying bioinformatics/machine learning/artificial intelligence tools to improve AF risk prediction.

Read more


Associations of relative fat mass and BMI with all-cause mortality: Confounding effect of muscle mass

Atrial fibrillation: better symptom control with rate and rhythm management

Birth cohort effect in atrial fibrillation: a matter of detection?

Clinical Predictors of Device-Detected Atrial Fibrillation During 2.5 Years After Cardiac Surgery: Prospective RACE V Cohort

Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction

Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference

Multimorbidity in patients with atrial fibrillation

Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study

Previous Exercise Levels and Outcome in Patients with New Atrial Fibrillation: 'Past Achievements Do Not Predict the Future'

Sex Differences in Outcomes of Patients with an Implantable Cardioverter-Defibrillator for the Secondary Prevention of Sudden Cardiac Death

Read more


Grootschalig onderzoek naar boezemfibrilleren

€2,5 miljoen subsidie Hartstichting voor onderzoek UMCG

Hartstichting geeft €2,5 miljoen subsidie voor boezemfibrilleren-onderzoek

€2,5 miljoen subsidie Hartstichting voor boezemfibrilleren-onderzoek

2,5 miljoen euro voor eerder en beter behandelen van boezemfibrilleren

€2,5 miljoen subsidie Hartstichting voor boezemfibrilleren-onderzoek

Targeted therapy effect on sinus rhythm in early AF may not stand the test of time

Vorhofflimmern: Kann Risikofaktor-Management Sinusrhythmus erhalten?

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

Read more